MLTX
Income statement / Annual
Last year (2023), MoonLake Immunotherapeutics's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, MoonLake Immunotherapeutics's net income was -$36.01 M.
See MoonLake Immunotherapeutics’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$13,158.00 |
$12,358.00 |
$4,971.00 |
$0.00 |
| Gross Profit |
-$13,158.00 |
-$12,358.00 |
-$4,971.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$31.80 M
|
$42.05 M
|
$35.52 M
|
$0.00
|
| General & Administrative
Expenses |
$22.32 M
|
$23.01 M
|
$21.66 M
|
$0.00
|
| Selling & Marketing
Expenses |
-$22.30 B
|
$0.00
|
$18.03 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$22.32 M
|
$23.01 M
|
$18.05 M
|
$105,755.00
|
| Other Expenses |
-$0.00 |
$591,732.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$54.12 M |
$65.06 M |
$53.57 M |
$105,755.00 |
| Cost And Expenses |
$54.12 M |
$65.06 M |
$53.58 M |
$105,755.00 |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$14,917.00 |
| Interest Expense |
$0.00 |
-$591,732.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$13,158.00
|
$12,358.00
|
$4,971.00
|
$206,297.00
|
| EBITDA |
-$54.11 M
|
-$65.06 M
|
-$53.57 M
|
-$105,760.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$10.14 M
|
$591,732.00
|
-$61,850.00
|
$14,922.00
|
| Income Before Tax |
-$43.98 M |
-$64.47 M |
-$53.64 M |
-$90,838.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$94,388.00 |
$36,366.00 |
$4,755.00 |
-$206,297.00 |
| Net Income |
-$36.01 M |
-$64.51 M |
-$53.64 M |
-$90,838.00 |
| Net Income Ratio |
0 |
0 |
0 |
0 |
| EPS |
-0.73 |
-2.2 |
-6.84 |
-0.0061 |
| EPS Diluted |
-0.73 |
-2.2 |
-6.84 |
-0.0061 |
| Weighted Average Shares
Out |
$49.12 M
|
$29.36 M
|
$7.84 M
|
$14.81 M
|
| Weighted Average Shares
Out Diluted |
$49.12 M
|
$29.36 M
|
$7.84 M
|
$14.81 M
|
| Link |
|
|
|
|
